Ret Proto-Oncogene Antikörper (pTyr905)

Produktnummer ABIN745523

Produktdetails anti-Ret Proto-Oncogene Antikörper

Target: Ret Proto-Oncogene (RET)

Bindungsspezifität: pTyr905

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Human, Maus

Homologie: Rat,Dog,Cow,Sheep,Pig,Chicken,Rabbit,Guinea Pig

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic phosphopeptide derived from human Ret around the phosphorylation site of Tyr905

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Andere Bezeichnung: Ret (RET Produkte)

Synonyme: c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper

Hintergrund:

Synonyms: C ret, Cadherin family member 12, Cadherin related family member 16, CDHF 12, CDHF12, CDHR16, ELKS Fusion gene, HSCR 1, HSCR1, Hydroxyaryl protein kinase, MEN2A, MEN2B, MTC 1, MTC1, Multiple endocrine neoplasia and medullary thyroid carcinoma 1, Oncogene RET, Proto oncogene tyrosine protein kinase receptor ret, Proto-oncogene c-Ret, Proto-oncogene tyrosine-protein kinase receptor ret, PTC, RET, RET ELE1, Ret Proto oncogene, RET transforming sequence, RET_HUMAN, RET51, RET9, tyrosine-protein kinase receptor ret.

Background: Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis, involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor, in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers, these diseases are characterized by aberrant integrins-regulated cell migration.

Gen-ID: 5979

Pathways: RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation